person · Reporting owner
Foundation Fighting Blindness Retinal Degeneration Fund
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Opus Genetics, Inc.IRD · Entity 5892 | Director · See Remarks | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Opus Genetics, Inc.
Report date September 30, 2026 · Filed October 02, 2026
Jointly reported with Foundation Fighting Blindness, Inc.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,236,171 |
Reported balance
After 2026-09-30 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-09-30 · Sale · Disposed 556,000 · Balance 3,236,171 F1: This transaction was executed in multiple trades at prices ranging from $4.95 to $5.29. The price reported in Column 4 is a weighted average price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Foundation Fighting Blindness, Inc. ("FFB") is the sole member of Foundation Fighting Blindness Retinal Degeneration Fund ("RDF") and may be deemed to beneficially own the securities owned directly by RDF. RDF has the power to vote and dispose of any securities directly owned by RDF. RDF's board of directors makes voting and investment decisions regarding securities held by RDF, subject to certain approval rights of the board of directors of FFB with respect to transactions exceeding a certain threshold. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $4.95 to $5.29. The price reported in Column 4 is a weighted average price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F2: Foundation Fighting Blindness, Inc. ("FFB") is the sole member of Foundation Fighting Blindness Retinal Degeneration Fund ("RDF") and may be deemed to beneficially own the securities owned directly by RDF. RDF has the power to vote and dispose of any securities directly owned by RDF. RDF's board of directors makes voting and investment decisions regarding securities held by RDF, subject to certain approval rights of the board of directors of FFB with respect to transactions exceeding a certain threshold.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 23:47 UTC | Opus Genetics, Inc. IRD · Entity 5892 | SaleCommon Stock | 556,000 | $4.96 | $2,755,980.80 |
DisclosureSEC source: 0002042266-26-000002 · primary_doc.xml · nonDerivative · entry 1 Foundation Fighting Blindness Retinal Degeneration Fund · CIK 0002042266 · Director · See Remarks Foundation Fighting Blindness, Inc. · CIK 0002042532 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,236,171 F1 · price: This transaction was executed in multiple trades at prices ranging from $4.95 to $5.29. The price reported in Column 4 is a weighted average price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.direct: Foundation Fighting Blindness, Inc. ("FFB") is the sole member of Foundation Fighting Blindness Retinal Degeneration Fund ("RDF") and may be deemed to beneficially own the securities owned directly by RDF. RDF has the power to vote and dispose of any securities directly owned by RDF. RDF's board of directors makes voting and investment decisions regarding securities held by RDF, subject to certain approval rights of the board of directors of FFB with respect to transactions exceeding a certain threshold. Read SEC document |
| May 18, 2026 Filed May 20, 2026 23:29 UTC | Opus Genetics, Inc. IRD · Entity 5892 | SaleCommon Stock | 1,700,000 | $4.35 | $7,395,000.00 |
DisclosureSEC source: 0002042266-26-000001 · primary_doc.xml · nonDerivative · entry 1 Foundation Fighting Blindness Retinal Degeneration Fund · CIK 0002042266 · Director · See Remarks Foundation Fighting Blindness, Inc. · CIK 0002042532 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,792,171 F1 · ownership.direct: Foundation Fighting Blindness, Inc. ("FFB") is the sole member of Foundation Fighting Blindness Retinal Degeneration Fund ("RDF") and may be deemed to beneficially own the securities owned directly by RDF. RDF has the power to vote and dispose of any securities directly owned by RDF. RDF's board of directors makes voting and investment decisions regarding securities held by RDF, subject to certain approval rights of the board of directors of FFB with respect to transactions exceeding a certain threshold. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 22:35 UTC | Opus Genetics, Inc. IRD · Entity 5892 | SaleCommon Stock | 4,000,000 | $2.15 | $8,600,000.00 |
DisclosureSEC source: 0002042266-25-000003 · primary_doc.xml · nonDerivative · entry 1 Foundation Fighting Blindness Retinal Degeneration Fund · CIK 0002042266 · Director · See Remarks Foundation Fighting Blindness, Inc. · CIK 0002042532 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,492,171 F1 · ownership.direct: Foundation Fighting Blindness, Inc. ("FFB") is the sole member of Foundation Fighting Blindness Retinal Degeneration Fund ("RDF") and may be deemed to beneficially own the securities owned directly by RDF. RDF has the power to vote and dispose of any securities directly owned by RDF. RDF's board of directors makes voting and investment decisions regarding securities held by RDF, subject to certain approval rights of the board of directors of FFB with respect to transactions exceeding a certain threshold. Read SEC document |
| May 05, 2025 Filed May 6, 2025 22:05 UTC | Opus Genetics, Inc. IRD · Entity 5892 | ConversionSeries A Non-Voting Convertible Preferred Stock · Derivative | 6,927.419 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001578563-25-000238 · primary_doc.xml · derivative · entry 2 Foundation Fighting Blindness Retinal Degeneration Fund · CIK 0002042266 · Director · 10% owner · See Remarks Foundation Fighting Blindness, Inc. · CIK 0002042532 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,927,419 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A non-voting convertible preferred stock (the "Preferred Stock") automatically converted into 1,000 shares of the Issuer's common stock as of 5:00 p.m. Eastern time on the third business day after the date that the Issuer's stockholders approved the conversion of the Preferred Stock into shares of the Issuer's common stock, which approval occurred on April 30, 2025. F3 · price: The shares of Preferred Stock were issued to the Reporting Persons in connection with a merger and reorganization in a stock-for-stock transaction. F1 · derivative.expiration_date: Each share of Series A non-voting convertible preferred stock (the "Preferred Stock") automatically converted into 1,000 shares of the Issuer's common stock as of 5:00 p.m. Eastern time on the third business day after the date that the Issuer's stockholders approved the conversion of the Preferred Stock into shares of the Issuer's common stock, which approval occurred on April 30, 2025. F2 · ownership.direct: Foundation Fighting Blindness, Inc. ("FFB") is the sole member of Foundation Fighting Blindness Retinal Degeneration Fund ("RDF") and may be deemed to beneficially own the securities owned directly by RDF. RDF has the power to vote and dispose of any securities directly owned by RDF. RDF's board of directors makes voting and investment decisions regarding securities held by RDF, subject to certain approval rights of the board of directors of FFB with respect to transactions exceeding a certain threshold. Read SEC document |
| May 05, 2025 Filed May 6, 2025 22:05 UTC | Opus Genetics, Inc. IRD · Entity 5892 | ConversionCommon Stock | 6,927,419 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001578563-25-000238 · primary_doc.xml · nonDerivative · entry 1 Foundation Fighting Blindness Retinal Degeneration Fund · CIK 0002042266 · Director · 10% owner · See Remarks Foundation Fighting Blindness, Inc. · CIK 0002042532 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,492,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A non-voting convertible preferred stock (the "Preferred Stock") automatically converted into 1,000 shares of the Issuer's common stock as of 5:00 p.m. Eastern time on the third business day after the date that the Issuer's stockholders approved the conversion of the Preferred Stock into shares of the Issuer's common stock, which approval occurred on April 30, 2025. F2 · ownership.direct: Foundation Fighting Blindness, Inc. ("FFB") is the sole member of Foundation Fighting Blindness Retinal Degeneration Fund ("RDF") and may be deemed to beneficially own the securities owned directly by RDF. RDF has the power to vote and dispose of any securities directly owned by RDF. RDF's board of directors makes voting and investment decisions regarding securities held by RDF, subject to certain approval rights of the board of directors of FFB with respect to transactions exceeding a certain threshold. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.